Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company
Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa, Kanagawa, President, CEO: Yoshinori Ikeura; Axcelead) announces that the company...
Axcelead’s response to the COVID-19 emergency declaration in January 2021
On January 7, the Japanese government declared State of Emergency to prevent the spread of COVID-19 pandemic...
Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline
Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases ...
Axcelead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development
Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc.(Axcelead, President: Yoshinori Ikeura)and Kyowa Kirin Co., Ltd....
Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications
June 29,2020- Otsuka Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug...
PassPort Technologies and Axcelead Drug Discovery Partners
Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active...